| Authors: |
Naing A; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA anaing@mdanderson.org., Lin CC; National Taiwan University Hospital, Taipei City, Taiwan., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA., Curigliano G; Istituto Europeo di Oncologia Biblioteca IRCCS, Milan, Lombardy, Italy.; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy., Burris HA; Sarah Cannon Research Institute LLC, Nashville, Tennessee, USA., Thistlethwaite F; Advanced Immunotherapy and Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., De Braud F; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Minchom A; Drug Development Unit, Royal Marsden Hospital, The Institute of Cancer Research - Sutton, London, UK., Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.; Universita degli Studi di Napoli Federico II, Naples, Campania, Italy., Wake M; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Nguyen MA; Sanofi, Frankfurt, Germany., Abbadessa G; Sanofi, Research and Development, Sanofi, Morristown, New Jersey, USA., Sainson RCA; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Palu CC; Sanofi, Cambridge, UK., Quaratino S; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Deantonio C; Sanofi, Cambridge, UK. |
